Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo pill for high blood pressure trial pulled before start

NCT ID NCT02493322

First seen Jun 25, 2026 · Last updated Jun 25, 2026

Summary

This study was designed to test whether a new fixed-dose combination of two blood pressure medicines (olmesartan and chlorthalidone) works as well as an existing combination (olmesartan and hydrochlorothiazide) in people with untreated high blood pressure. The trial was withdrawn before any participants were enrolled, so no data were collected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL ARTERIAL HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

olmesartan medoxomil + chlorthalidone (fixed-dose combination)

What this could lead to

If successful, this could offer a new once-daily pill option for controlling high blood pressure.

What could go wrong

The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination would have been safer or more effective than existing treatments.

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.